1265295-21-3
Chemical Structure
Selexipag-d7
- CAS No.: 1265295-21-3
- Formula:C26H25D7N4O4S
- Molecular Weight:503.66
IUPAC Name: 2-(4-((5,6-diphenylpyrazin-2-yl)(propan-2-yl-d7)amino)butoxy)-N-(methylsulfonyl)acetamide
InChIKey: QXWZQTURMXZVHJ-ZGBMZCDDSA-N
SMILES: CS(NC(COCCCCN(C1=CN=C(C2=CC=CC=C2)C(C3=CC=CC=C3)=N1)C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)(=O)=O
Biological Activity: Selexipag-d7 is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Selexipag-d7 | 98.44% | Selexipag-d7 is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selexipag (Standard) | ≥98% | Selexipag (Standard) is the analytical standard of Selexipag. This product is intended for research and analytical applications. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selexipag-d6 | Selexipag-d6 is deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selexipag | 99.86% | Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Kuwano K, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007 Sep;322(3):1181-8. [Content Brief]